tirzepatide safer than semaglutide vs. Semaglutide: Which is Best for Weight Loss? We're excited to share new,

Your body may release less growth hormone as a result

GIP activation improves sugar processing and helps regulate insulin levels

The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword

Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone